Influence of fluor salts, hormone replacement therapy and calcitonin on the concentration of insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor-beta 1 in human iliac crest bone matrix from patients with primary osteoporosis.
OBJECTIVE
Data from cell culture experiments suggest that local growth factors (GFs) may mediate the effects of estrogens, calcitonin or fluor ions on the skeleton. To assess the in vivo relevance of the in vitro reports, the effect of fluor salts, hormone replacement therapy (HRT) and calcitonin on the concentrations of IGF-I, IGF-II and transforming growth factor (TGF)-beta 1 in bone matrix extracts from osteoporotic patients was evaluated.


METHODS
Iliac crest bone biopsies were obtained from 170 patients (76 men and 94 women) with primary osteoporosis aged 55.5+/-0.8 Years.


METHODS
Bone matrix extraction was performed based on a guanidine-HCl/ethylendiamine-tetra-acetic acid method.


RESULTS
In comparison with age- and body mass index (BMI)-matched controls, no influence of long-term therapy with fluor ions (n=41) or calcitonin (n=16) on the bone matrix concentration of GFs was noticed. Postmenopausal women with osteoporosis on HRT (n=39) had lower skeletal IGF-I but not IGF-II levels as compared with age- and BMI-matched non-users. However, the lower rate of bone turnover in women with HRT may account for this difference, since the significance was lost after adjustment for alkaline phosphatase. Likewise, a tendency for lower TGF-beta 1 levels was observed in HRT users as compared with non-users but was lost after adjustment for bone turnover. None of the therapies influenced the serum levels of GFs when patients receiving continuous therapy for at least 1 Year before bone biopsy were considered.


CONCLUSIONS
Our data suggest no direct effect of fluor therapy on skeletal GFs levels. At the concentrations used, neither HRT nor calcitonin appeared to exert any significant influence on serum or bone matrix GF levels.
Pepene
C E
CE
Department of Internal Medicine I, University of Heidelberg, Heidelberg, Germany. carmenpepene@yahoo.com
Seck
T
T
Diel
I
I
Minne
H W
HW
Ziegler
R
R
Pfeilschifter
J
J
D001706:Biopsy; D015519:Bone Density / Q000187:drug effects; D002116:Calcitonin / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D006133:Growth Substances / Q000378:metabolism*; D006801:Humans; D007085:Ilium / Q000187:drug effects / Q000473:pathology; D066298:In Vitro Techniques; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007335:Insulin-Like Growth Factor II / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000378:metabolism* / Q000473:pathology; D012969:Sodium Fluoride / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta / Q000378:metabolism; D053773:Transforming Growth Factor beta1
D006133:Growth Substances; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D012969:Sodium Fluoride; D002116:Calcitonin